JP2004529108A5 - - Google Patents

Download PDF

Info

Publication number
JP2004529108A5
JP2004529108A5 JP2002569154A JP2002569154A JP2004529108A5 JP 2004529108 A5 JP2004529108 A5 JP 2004529108A5 JP 2002569154 A JP2002569154 A JP 2002569154A JP 2002569154 A JP2002569154 A JP 2002569154A JP 2004529108 A5 JP2004529108 A5 JP 2004529108A5
Authority
JP
Japan
Prior art keywords
physiologically acceptable
acceptable salt
salmeterol
pharmaceutical
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002569154A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004529108A (ja
Filing date
Publication date
Priority claimed from GBGB0105560.7A external-priority patent/GB0105560D0/en
Application filed filed Critical
Publication of JP2004529108A publication Critical patent/JP2004529108A/ja
Publication of JP2004529108A5 publication Critical patent/JP2004529108A5/ja
Pending legal-status Critical Current

Links

JP2002569154A 2001-03-07 2002-03-04 R−サルメテロールおよびプロピオン酸フルチカゾンを含んでなる医薬製剤 Pending JP2004529108A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0105560.7A GB0105560D0 (en) 2001-03-07 2001-03-07 Pharmaceutical formulations
PCT/GB2002/000909 WO2002069979A2 (en) 2001-03-07 2002-03-04 Pharmaceutical formulation comprising r-salmeterol and fluticasone propionate

Publications (2)

Publication Number Publication Date
JP2004529108A JP2004529108A (ja) 2004-09-24
JP2004529108A5 true JP2004529108A5 (enExample) 2005-12-22

Family

ID=9910112

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002569154A Pending JP2004529108A (ja) 2001-03-07 2002-03-04 R−サルメテロールおよびプロピオン酸フルチカゾンを含んでなる医薬製剤

Country Status (6)

Country Link
US (1) US20040136918A1 (enExample)
EP (1) EP1365767A2 (enExample)
JP (1) JP2004529108A (enExample)
AU (1) AU2002237400A1 (enExample)
GB (1) GB0105560D0 (enExample)
WO (1) WO2002069979A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US7811606B2 (en) * 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
AU2004270171A1 (en) * 2003-08-29 2005-03-17 Glaxo Group Limited Pharmaceutical metered dose inhaler and methods relating thereto
KR20070102659A (ko) * 2004-09-09 2007-10-19 씨아이피엘에이 엘티디. 베타작용제의 이성체 및 항-콜린제를 포함하는 약제학적조성물
EP2486942B1 (en) * 2004-11-24 2018-10-10 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US8758816B2 (en) * 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US9119777B2 (en) * 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
US8415390B2 (en) * 2008-05-30 2013-04-09 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
TR201000685A2 (tr) * 2010-01-29 2011-08-22 Bi̇lgi̇ç Mahmut Salmeterol ve flutikazon içeren farmasötik preparatlar.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL95936A (en) * 1989-10-10 1996-01-19 Glaxo Group Ltd ) R (-) - (- Hydroxy- (A-]]] 6-) 4- Phenylbutoxy (xyl [amino] methyl [-1,3-benzenedimethanol, its preparation and pharmaceutical preparations containing it
US5919827A (en) * 1990-07-11 1999-07-06 Sepracor Inc. Method for treating asthma using optically pure R(-) salmeterol
AP979A (en) * 1995-04-14 2001-06-28 Glaxo Wellcome Inc Metered dose imhaler for salmeterol.
SK284448B6 (sk) * 1995-04-14 2005-04-01 Glaxo Wellcome Inc. Merací dávkovací inhalátor
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US6136294C1 (en) * 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
AU2206801A (en) * 1999-12-24 2001-07-09 Alan Leslie Cripps Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate

Similar Documents

Publication Publication Date Title
RU2019100425A (ru) Новая доза и препаративная форма
HRP20130835T1 (hr) Farmaceutske formulacije otopine za davanje kao stlaäśeni inhalat u inhalatoru
RU98118908A (ru) Баллон для доставки фармацевтического состава, дозирующий ингалятор
GR3018168T3 (en) Medicaments.
RU2010108640A (ru) Новая комбинация терапевтических агентов
JP2016040316A5 (enExample)
RU2001126347A (ru) Композиции, включающие формотерол и фуроат мометасона, предназначенные для лечения астмы
CA2447510A1 (en) Fluorocarbon aerosol medicaments
JP5800829B2 (ja) Copd用エアロゾル製剤
ATE308317T1 (de) Zubereitungen mit einem anticholinergischen wirkstoff für die behandlung der chronischen obstruktiven lungenerkrankung
ATE368450T1 (de) Pharmazeutische aerosolzubereitung, die hfa227 und hfa 134a enthält
JP2003518484A5 (enExample)
JP2004529108A5 (enExample)
JP2005508963A5 (enExample)
NZ600208A (en) Inhalation solutions
MX2023003754A (es) Formulacion farmaceutica para inhalador presurizado de dosis medidas.
HRP20160630T1 (hr) Farmaceutske aerosolne formulacije formoterola i beklometazon-dipropionata
US20130104881A1 (en) Stabilized Metered Dose Inhaler
JP2005514440A (ja) アミドおよび/またはエステルを含有する、賦形剤化合物を含む、医用エアロゾル組成物
RU2020112519A (ru) Ингалятор и сетка для ингалятора
ES2259915B1 (es) Nueva formulacion estable de aerosoles en suspension y procedimiento de obtencion.
US20230057979A1 (en) Medicinal compositions for carbon dioxide based metered dose inhalers
JP2006508993A5 (enExample)
WO2004103339A3 (en) Improved metered dose inhaler
Linne-Geyer et al. P291 In-use stability of aclidinium bromide 400 μg/formoterol fumarate dihydrate 12 μg inhalation powder in a dry powder inhaler